Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. 2005

Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
Department of Pediatric Oncology/Hematology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.

Glucocorticoid sensitivity is an important prognostic factor in pediatric acute lymphoblastic leukemia (ALL). For its antileukemic effect, glucocorticoid binds the intracellular glucocorticoid receptor (GR) subsequently regulating transcription of downstream genes. We analyzed whether genetic variations within the GR gene are related to differences in the cellular response to glucocorticoids. METHODS In leukemic samples of 57 children, the GR gene was screened for nucleotide variations using a PCR/single-strand conformational polymorphism sequencing strategy. Data were linked to in vivo and in vitro glucocorticoid resistance. RESULTS No somatic mutations were detected in the GR gene coding region, but six polymorphisms (i.e., ER22/23EK, N363S, BclI, intron mutation 16 bp upstream of exon 5, H588H, and N766N) were identified. In 67% of ALL cases, at least one minor allele of these polymorphisms was detected. Although only borderline significant, the incidence for the N363S polymorphism minor allele was higher (12% versus 6%, P = 0.06) and for the ER22/23EK minor allele lower (4% versus 7.6%, P = 0.1) than in a healthy, comparable population. The different genotypes of the polymorphisms were not related to prednisone resistance. In conclusion, polymorphisms but not somatic mutations in the GR gene coding region occur in leukemic blasts of children with ALL. Our data suggest that these genetic variations are not a major contributor for differences in cellular response to glucocorticoids in childhood ALL. The higher incidence of the N363S minor allele and the lower incidence of the ER22/23EK minor allele in our ALL population as compared with a normal population warrants further research.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011965 Receptors, Glucocorticoid Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example. Corticoid Type II Receptor,Glucocorticoid Receptors,Glucocorticoids Receptor,Corticoid II Receptor,Corticoid Type II Receptors,Glucocorticoid Receptor,Receptors, Corticoid II,Receptors, Corticoid Type II,Receptors, Glucocorticoids,Corticoid II Receptors,Glucocorticoids Receptors,Receptor, Corticoid II,Receptor, Glucocorticoid,Receptor, Glucocorticoids
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
January 2022, Frontiers in pediatrics,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
April 2022, The Journal of steroid biochemistry and molecular biology,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
April 2010, Leukemia research,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
November 2003, Haematologica,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
December 1980, Blood,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
March 2023, Pharmacogenomics,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
August 2000, Leukemia & lymphoma,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
May 2015, Die Pharmazie,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
February 2005, The Journal of steroid biochemistry and molecular biology,
Wim J E Tissing, and Jules P P Meijerink, and Monique L den Boer, and Bas Brinkhof, and Elisabeth F C van Rossum, and Elisabeth R van Wering, and Jan W Koper, and Pieter Sonneveld, and Rob Pieters
December 2018, Cancer cell,
Copied contents to your clipboard!